Stocks
ETFs
Options
Commodities
Crypto
Currency
Pro Newsletters
Research Tools
Daily Feeds
Calendars
Economic Indicators
Class Actions
Calculators
Education
About Us
Working with TipRanks
Follow Us
Medicenna Therapeutics Corp (TSE:MDNA)
TSX:MDNA
Holding TSE:MDNA?
Track your performance easily
MDNA Stock Chart & Stats
Day’s Range― - ―
52-Week RangeC$0.41 - C$2.98
Previous CloseN/A
Volume26.49K
Average Volume (3M)68.92K
Market Cap
C$104.81M
Enterprise ValueC$114.97M
Total Cash (Recent Filing)$14.04M
Total Debt (Recent Filing)N/A
Price to Earnings (P/E)―
Beta1.73
Next Earnings
Feb 06, 2025EPS Estimate
-0.06Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)-0.37
Shares Outstanding78,215,750
10 Day Avg. Volume62,700
30 Day Avg. Volume68,925
Standard Deviation0.35
R-Squared0.02
Alpha0.02
Financial Highlights & Ratios
PEG RatioN/A
Price to Book (P/B)N/A
Price to Sales (P/S)N/A
Price to Cash Flow (P/CF)-4.70
P/FCF Ratio0.00
Enterprise Value/Market Cap1.10
Enterprise Value/RevenueN/A
Enterprise Value/Gross ProfitN/A
Enterprise Value/Ebitda-4.31
Forecast
1Y Price Target
C$5.79Price Target Upside338.64% Upside
Rating ConsensusStrong Buy
Number of Analyst Covering3
Medicenna Therapeutics Corp News
PremiumCompany Announcements
Medicenna’s MDNA11 Shows Promise in Cancer Treatment
PremiumCompany Announcements
Medicenna’s MDNA11 Shows Promising Cancer Treatment Results
PremiumCompany Announcements
Medicenna Unveils New Data on Cancer Treatment
PremiumCompany Announcements
Medicenna’s Innovative Cancer Therapies Show Promise
PremiumCompany Announcements
Medicenna Showcases Promising Results and Strong Financials
PremiumCompany Announcements
Medicenna to Present Innovative Cancer Data at ConferencesPremiumCompany Announcements
Medicenna Reports Promising Results with MDNA11PremiumCompany Announcements
Medicenna Announces Breakthroughs in Cancer TreatmentBulls Say, Bears Say
Bulls Say
Clinical SuccessInitial safety data has led to the approval for enrollment of higher dose cohorts, indicating a promising outlook for further trials.
Financial StabilityThe cash runway extends into mid-calendar 2026, providing financial stability for ongoing operations.
Therapeutic AdvancementsMDNA11 monotherapy efficacy in CPI-failed patients reported an additional PR in melanoma, bringing overall ORR for all patients treated at ≥60 ug/kg to 5/20 (25%), and 3/13 (23%) in melanoma.
Bears Say
Efficacy UncertaintyIt is still too early to determine the efficacy of the combo data, necessitating further investigation.
Response RateThe overall response rate in the combination arm is considered low, highlighting the need for more data.
Response Rate DeclineORR dips on NMSC.
---
Options Prices
Currently, No data available
---
Ownership Overview
15.07% Insiders
0.15% Other Institutional Investors
84.78% Public Companies and
Individual Investors
MDNA FAQ
What was Medicenna Therapeutics Corp’s price range in the past 12 months?
Medicenna Therapeutics Corp lowest stock price was C$0.41 and its highest was C$2.98 in the past 12 months.
What is Medicenna Therapeutics Corp’s market cap?
Medicenna Therapeutics Corp’s market cap is C$104.81M.
When is Medicenna Therapeutics Corp’s upcoming earnings report date?
Medicenna Therapeutics Corp’s upcoming earnings report date is Feb 06, 2025 which is in 4 days.
How were Medicenna Therapeutics Corp’s earnings last quarter?
Medicenna Therapeutics Corp released its earnings results on Nov 15, 2024. The company reported -C$0.05 earnings per share for the quarter, beating the consensus estimate of -C$0.065 by C$0.015.
Is Medicenna Therapeutics Corp overvalued?
According to Wall Street analysts Medicenna Therapeutics Corp’s price is currently Undervalued.
Does Medicenna Therapeutics Corp pay dividends?
Medicenna Therapeutics Corp does not currently pay dividends.
What is Medicenna Therapeutics Corp’s EPS estimate?
Medicenna Therapeutics Corp’s EPS estimate is -0.06.
How many shares outstanding does Medicenna Therapeutics Corp have?
Medicenna Therapeutics Corp has 78,215,750 shares outstanding.
What happened to Medicenna Therapeutics Corp’s price movement after its last earnings report?
Medicenna Therapeutics Corp reported an EPS of -C$0.05 in its last earnings report, beating expectations of -C$0.065. Following the earnings report the stock price went down -14.706%.
Which hedge fund is a major shareholder of Medicenna Therapeutics Corp?
Currently, no hedge funds are holding shares in TSE:MDNA
---
Medicenna Therapeutics Corp Stock Smart Score
Unlock Smart Score
1
2
3
4
5
6
7
8
9
10
Analyst Consensus
Strong Buy
Average Price Target:
C$5.79 (338.64% Upside)
C$5.79 (338.64% Upside)
Blogger Sentiment
Bullish
TSE:MDNA Sentiment 100%
Sector Average 71%
Sector Average 71%
Insider Transactions
Bought Shares
Worth C$29.0K over
the Last 3 Months
the Last 3 Months
Technicals
SMA
Negative
20 days / 200 days
Momentum
204.54%
12-Months-Change
Fundamentals
Return on Equity
-133.06%
Trailing 12-Months
Asset Growth
18.69%
Trailing 12-Months
Company Description
Medicenna Therapeutics Corp
Medicenna Therapeutics Corp is a Canada based immuno-oncology company. Its principal business activity is the development and commercialization of Empowered Cytokines and Superkines for the treatment of cancer. The company is engaged in developing Interleukin-4 Empowered Cytokines (IL4-ECs) that specifically target the Interleukin-4 Receptor (IL4R) which is over-expressed by 20 different cancers, cancer stem cells and immunosuppressive cells of the tumor microenvironment. The IL4-ECs have the potential to purge the tumor and un-blind the immune system to cancer thereby altering the treatment paradigm for a large majority of cancer patients.
---
MDNA Stock 12 Month Forecast
Average Price Target
C$5.79
▲(338.64% Upside)
Technical Analysis
Best Analysts Covering MDNA
1 Year
1 Year Success Rate
6/7 ratings generated profit
1 Year Average Return
+236.44%
reiterated a buy rating 12 months ago
Copying Andre Uddin's trades and holding each position for 1 Year would result in 85.71% of your transactions generating a profit, with an average return of +236.44% per trade.
---